( London: Statistics from a Phase III stu...)GlaxoSmithKline’s Tykerb is to Be Started Earlier in Breast Cancer, Study Find,Health

London: Statistics from a Phase III study has shown that GlaxoSmithKline's Tykerb along with Roche's Xeloda is far better than Xeloda alone in women with HER2// positive advanced breast cancer, where the disease had progressed despite previous therapy involving Herceptin.

Basis the findings, researchers opined that, Tykerb should be checked out for its use during the early treatment of HER2 positive breast cancer.

"Patients with advanced or metastatic HER2 positive breast cancer have limited options once their cancer has progressed on trastuzumab and standard initial chemotherapy regimens. There has been a clear need for alternative treatments to help women with metastatic breast cancer in this advanced setting. Lapatinib combined with capecitabine has demonstrated superior efficacy over capecitabine alone in this group of patients and we look forward to it being made available to women suffering from this devastating disease," said lead investigator Charles Geyer, Director of Breast Medical Oncology at Allegheny General Hospital, Pittsburgh, Pennsylvania, U.S.

Women suffering HER2 positive breast cancer carry an enhanced risk of advancement of disease and death as against women suffering tumors.
'"/>




Page: 1
Related medicine news :

1. GlaxoSmithKline’s Epilepsy Drug given the Green Signal by FD
2. GSK Seeks Permission to Market Breast Cancer Pill Tykerb
3. International Osteoporosis Research Centre To Be Started In India.
4. New Test Can Detect Breast Cancer 8 Years Earlier
5. Earlier the better to start healthy diets
6. Gum Disease Affects Diabetic Children Earlier Than Anticipated
7. Earlier Introduction of Solid Foods in Infants Could Prevent Wheat Allergy
8. Earlier the Cochlear Implants Used Better the Speech
9. Profiling of Cancer Genes May Lead to Earlier Detection Human Cancers
10. Hay Fever Season may Begin Earlier, Warns Experts
11. Diabetes Risk Factors Develop Earlier in Women Than Men